Arthur Butcher Net Worth

The estimated Net Worth of Arthur C Butcher is at least $52.2 Миллион dollars as of 26 August 2024. Mr. Butcher owns over 14,012 units of Boston Scientific stock worth over $895,918 and over the last 8 years he sold BSX stock worth over $51,303,653. In addition, he makes $0 as Executive Vice President and President и Asia Pacific at Boston Scientific.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Butcher BSX stock SEC Form 4 insiders trading

Arthur has made over 60 trades of the Boston Scientific stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 14,012 units of BSX stock worth $1,110,451 on 26 August 2024.

The largest trade he's ever made was selling 27,000 units of Boston Scientific stock on 3 February 2023 worth over $1,315,980. On average, Arthur trades about 4,230 units every 37 days since 2017. As of 26 August 2024 he still owns at least 10,802 units of Boston Scientific stock.

You can see the complete history of Mr. Butcher stock trades at the bottom of the page.

Arthur Butcher biography

Arthur C. Butcher serves as Executive Vice President and President, Asia Pacific of the Company. In this role, he is responsible for developing and bringing to market less invasive devices for treating gastrointestinal and pulmonary conditions. Prior to his current role, Mr. Butcher served as vice president & general manager, Japan Endoscopy from August 2014 to June 2016. Mr. Butcher has held a variety of marketing and strategic planning management positions within the Endoscopy and Urology and Pelvic Health businesses, including vice president of Global Marketing, Endoscopy division from April 2011 to August 2014, and vice president of New Business Development and Strategic Planning, Urology & Women's Health. Since joining Boston Scientific in 1997, Mr. Butcher has held management roles with increasing responsibility bringing a deep experience across divisions. He holds a B.A. in International Relations from the University of Pennsylvania and an M.B.A. from Columbia University.

How old is Arthur Butcher?

Arthur Butcher is 49, he's been the Executive Vice President and President и Asia Pacific of Boston Scientific since 2020. There are 26 older and 3 younger executives at Boston Scientific. The oldest executive at Boston Scientific Corp. is Yoshiaki Fujimori, 69, who is the Independent Director.

What's Arthur Butcher's mailing address?

Arthur's mailing address filed with the SEC is 300 BOSTON SCIENTIFIC WAY, , MARLBOROUGH, MA, 01752-1234.

Insiders trading at Boston Scientific

Over the last 20 years, insiders at Boston Scientific have traded over $938,841,783 worth of Boston Scientific stock and bought 1,398,972 units worth $16,231,539 . The most active insiders traders include Peter M Nicholas, John E Abele и Michael F Mahoney. On average, Boston Scientific executives and independent directors trade stock every 3 days with the average trade being worth of $4,899,929. The most recent stock trade was executed by Michael F Mahoney on 5 September 2024, trading 162,777 units of BSX stock currently worth $13,212,609.

What does Boston Scientific do?

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.

Complete history of Mr. Butcher stock trades at Staar Surgical Co и Boston Scientific

Boston Scientific executives and stock owners

Boston Scientific executives and other stock owners filed with the SEC include:

• Michael Mahoney,
  Chairman of the Board, President, Chief Executive Officer
• Daniel Brennan,
  Chief Financial Officer, Executive Vice President
• Joseph Fitzgerald,
  Executive Vice President, President, Interventional Cardiology
• Edward Mackey,
  Executive Vice President - Operations
• David Pierce,
  Executive Vice President and President, MedSurg and President, Endoscopy
• Michael F. Mahoney,
  Chairman, Pres & CEO
• Daniel J. Brennan,
  Exec. VP & CFO
• Joseph M. Fitzgerald,
  Exec. VP & Pres of Interventional Cardiology
• Edward F. Mackey,
  Exec. VP of Global Operations
• Jeffrey B. Mirviss,
  Exec. VP & Pres of Peripheral Interventions
• Edward Ludwig,
  Lead Independent Director
• Charles Dockendorff,
  Independent Director
• David Roux,
  Independent Director
• John Sununu,
  Independent Director
• Donna James,
  Independent Director
• Nelda Connors,
  Independent Director
• Ellen Zane,
  Independent Director
• Stephen MacMillan,
  Independent Director
• Yoshiaki Fujimori,
  Independent Director
• John Sorenson,
  Senior Vice President - Manufacturing and Supply Chain
• Meghan Scanlon,
  Senior Vice President and President, Urology and Pelvic Health
• Scott Olson,
  Senior Vice President and President, Rhythm Management
• Maulik Nanavaty,
  Senior Vice President and President - Neuromodulation
• Wendy Carruthers,
  Senior Vice President - Human Resources
• Desiree Ralls-Morrison,
  Senior Vice President, General Counsel, Corporate Secretary
• Jodi Eddy,
  Senior Vice President, Chief Information Officer
• Eric Thepaut,
  Executive Vice President and President - Europe, Middle East and Africa
• Jeffrey Mirviss,
  Executive Vice President and President - Peripheral Interventions
• Ian Meredith,
  Executive Vice President, Global Chief Medical Officer
• Arthur Butcher,
  Executive Vice President and President, Asia Pacific
• Catherine Jennings,
  VP of Global Marketing & New Bus. Devel. of Peripheral Interventions
• Vance R. Brown,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Susan Vissers Lisa,
  VP of Investor Relations
• Jodi Euerle Eddy,
  Sr. VP and Chief Information & Digital Officer
• Jonathan R Monson,
  VP, Global Controller & Chief Accounting Officer
• Vance R Brown,
  SVP, GC and Corp. Secretary
• Timothy A. Pratt,
  EVP & General Counsel
• Supratim Bose,
  EVP & President, Asia-Pacific
• Michael P. Phalen,
  SVP & President, Endoscopy
• Keith D Dawkins,
  Sr. VP, Chief Medical Officer
• Kevin J. Ballinger,
  EVP & Pres, Interven Cardio
• Cheryl Pegus,
  Director
• David S Wichmann,
  Director
• Xin Warren Wang,
  SVP and Pres, Asia Pacific
• Peter M Nicholas,
  Director
• Kristina M Johnson,
  Director
• Nicholas J Jr Nicholas,
  Director
• Karen Prange,
  SVP&Pres, Uro & Women's Health
• Ernest Mario,
  Director
• John E Abele,
  Director
• Uwe E Reinhardt,
  Director
• Katharine T Bartlett,
  Director
• Jean Fitterer Lance,
  SVP & Chief Compliance Officer
• Kenneth Pucel,
  EVP, Operations
• Bruce L Byrnes,
  Director
• John Michael Onuscheck,
  SVP & Pres-Neuromodulation
• Jeffrey D Capello,
  Chief Accounting Officer
• Otha T. Iii Spriggs,
  SVP, Human Resources
• William Kucheman,
  SVP & Group President
• John Raymond Elliott,
  Director
• Lawrence R Neumann,
  SVP and Pres, Emerging Markets
• John B. Pedersen,
  Pres,Uro & Women's Health
• Brian R Burns,
  SVP - Quality
• Ray J Groves,
  Director
• Sam R Leno,
  CFO & EVP Finance & IS
• Stephen F Moreci,
  Sr. VP, Endosurgery
• Marye Anne Fox,
  Director
• Fred Colen,
  EVP
• John E Pepper,
  Director
• James Gilbert,
  EVP
• Donovan Paul,
  SVP, Corporate Comm
• David W Mc Faul,
  Senior VP International
• Ursula M Burns,
  Director
• Warren B Rudman,
  Director
• William F Jr Mcconnell,
  SVP, Administration CRM
• Donald S Baim,
  EVP, Chief Med. & Sci. Officer
• Lucia Luce Quinn,
  Exec. Vice President-HR
• James R Tobin,
  President & CEO
• Paul W Sandman,
  EVP and General Counsel
• Paul A Laviolette,
  COO
• Nancy Ann Deparle,
  Director
• Joel Lawrence Fleishman,
  Director
• David C Habiger,
  Director
• Jonathan Monson,
  SVP, Global Controller and CAO
• Emily Woodworth,
  SVP, Global Controller and CAO
• Jessica L Mega,
  Director
• Susan E Morano,
  Director